

ASX Release

## **2024 Annual General Meeting -address by Executive Chair**

ADELAIDE, 14 November 2024: Anatara Lifesciences (ASX: ANR or “the Company”) presents the address by Executive Chair, Dr. David Brookes.

Dear Shareholders,

Thank you for your continued support and investment in Anatara Lifesciences. The Company’s activities remain dominated by the progress of the GaRP-IBS Phase II trial. We have continued to carefully manage the Company’s finances and processes to support this high-quality trial, while looking to develop other opportunities also with the potential to make a difference to unmet health needs, which thereby create shareholder value.

The Phase II trial of GaRP for IBS (Irritable Bowel Syndrome) selects sufferers of this complex disorder in the moderate to moderately severe categories of the IBS subtypes D (Diarrhoeal predominate) and M (mixed pattern). We have continued to provide regular updates on the progress of Stage 2 of the trial, with the expectation that the promising results from Stage 1 announced on the 28<sup>th</sup> of September 2023 will be corroborated. As of yesterday, the numbers were 50 enrolled and over 30 in screening with the trial design having a minimum of 60 to be enrolled in Stage 2. Our thanks, as always, go to all the IBS sufferers who expressed interest in being involved in the trial and particularly those who have been able to participate. We at Anatara absolutely understand the difficulty of committing with this condition to a quality, stringent trial and also appreciate the support and oversight of the trial site staff.

The focus on assessing other opportunities and assets to broaden Anatara’s human health portfolio continues with the addition of a new anti-obesity project. This anti-obesity project has been designed to develop an oral medication to assist weight reduction and sustaining weight control in conjunction with other contemporary treatments and approaches. Obesity (BMI of 30 kg/m<sup>2</sup> or greater) is a medical condition of such prevalence that it is described as a new pandemic, with associated significant comorbidities and health risk factors. At a time of already stretched health systems, individuals will need further strategies and treatments to those currently available to manage, control and prevent obesity and rebound weight gain. The details of this project remain confidential until such time that we have confirmed Proof of Concept and have security around the know-how and IP involved in the formulations.

We went into a halt for a capital raise on Wednesday 13<sup>th</sup> of November (yesterday) and I am pleased to be able to state that is in the form of a placement to sophisticated investment groups and individuals to be followed by an SPP on the same terms.

As I stated in the Annual Report, Anatara’s small team are very dedicated to building the Company’s projects and shareholder value. I take this opportunity to thank the management team, our consultants and fellow Board members for their expertise, with every confidence that we have in place the skills and resources to create an exciting company. I also take this opportunity to thank Mr. Steven Denaro who will retire as Company Secretary at the end of this month after many years of service throughout Anatara’s ASX history from pre-listing days.



On behalf of the Anatara Board and management team, our sincere thanks again to our shareholders for their support. The GaRP product with broad gastrointestinal health indications has confirmed promise and we remain inspired to commercialise evidence-based solutions for disorders with a focus on those involving the complexities of the gastrointestinal health and look forward to keeping you informed on our progress.

Yours sincerely,



Dr. David Brookes

Executive Chair.

### About GaRP

Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. GaRP is the working name for the product from the Company's **G**astrointestinal **Re**Programming project that was designed to assist restoration and maintenance of the gastrointestinal tract (GIT) lining as a barrier and assist the homeostasis of the microbiome. The product is made of GRAS (Generally Regarded As Safe) components.

For more information please contact:

Dr. David Brookes  
Chair, Anatara Lifesciences Ltd  
+61 (0) 411 712 579  
[dbrookes@anatara.com](mailto:dbrookes@anatara.com)

Dirk van Dissel  
Candour Advisory – Investor Relations  
+61 (0) 408 326 367  
[dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)



## About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

## Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

## Anatara Lifesciences Limited

### Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email [info@anatara.com](mailto:info@anatara.com) | Website [anatalifesciences.com](http://anatalifesciences.com)

